ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

エチドロン酸

Etidronic Acid

HCID 3305
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
2809-21-4
標準SMILES
CC(O)(P(=O)(O)O)P(=O)(O)O
InChIKey
DBVJJBKOTRCVKF-UHFFFAOYSA-N
分子式
C2H8O7P2
平均分子量
206.03 g/mol
単同位体質量
205.97452659

概要

Etidronic acid is a 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces. It has a role as an antineoplastic agent, a chelator and a bone density conservation agent. It is a conjugate acid of an etidronic acid(2-).

名称と識別子

優先名称
Etidronic Acid
IUPAC
(1-hydroxy-1-phosphonoethyl)phosphonic acid
現地名
エチドロン酸
英語名
Etidronic Acid
分子式
C2H8O7P2
分子量
206.03

名称と別名

Etidronic acid2809-21-4HEDP1-Hydroxyethylidene-1,1-diphosphonic acidEHDPEtidronsaeureTurpinal SLAcetodiphosphonic acidHydroxyethanediphosphonic acidAcido etidronicoAcide etidroniqueOxyethylidenediphosphonic acid
名称をさらに表示
1-ヒドロキシエタン-1,1-ジホスホン酸 (約60%水溶液, 約4.2mol/L)ツルピナールSL(1-ヒドロキシエタン-1,1-ジイル)ビスホスホン酸(1-ヒドロキシ-1,1-エタンジイル)ビスホスホン酸1-ヒドロキシエタン-1,1-ジイルビスホスホン酸1-ヒドロキシエタン-1,1-ジホスホン酸デクエスト20151-ヒドロキシエチリデンビス(ホスホン酸)1-ヒドロキシエチリデンビスホスホン酸ヒドロキシ(メチル)メチレンビスホスホン酸1,1-ジホスホノエタノールキシジホンデクエストZ-010フェロホス510(1-ヒドロキシエチリデン)ビスホスホン酸ウェイプレックス1-ホスホノ-1-ヒドロキシエチルホスホン酸エチドロン酸[ヒドロキシ(メチル)メチレン]ビスホスホン酸デクエスト2010HEDP2NA1-diphosphonic acid1-HYDROXYETHYLIDENE-1HEDPA
Dequest 2015Dequest Z 010Ferrofos 510Dequest 20101-Hydroxyethane-1,1-diphosphonic acidDiphosphonate (base)1-Hydroxyethanediphosphonic acidPhosphonic acid, (1-hydroxyethylidene)bis-

物性

構造計算による物性

XLogP
-3.7
極性表面積
135 Ų
水素結合供与体数
5
水素結合受容体数
7
回転可能結合数
2
重原子数
11
形式電荷
0
複雑度
211

実験および物理化学的性質

Chemical ClassesOther Classes -> Organic Acids
Drugs · 2 件

Pharmaceuticals

Pharmaceuticals -> Listed in ZINC15

Cosmetics · 2 件

Cosmetic ingredients (Etidronic Acid) -> CIR (Cosmetic Ingredient Review)

Chelating

FragrancesFragrance Ingredient (Phosphonic acid, (1-hydroxyethylidene)bis-) -> IFRA transparency List
LogP-3.8
Food AdditivesBOILER WATER ADDITIVE -> FDA Substance added to food
Solubility1.15e+01 g/L
Human DrugsBreast Feeding; Lactation; Bisphosphonates; Bone Density Conservation Agents; Diphosphonates;
Melting Point · 2 件

198-199

105 °C

Food Contact Substances · 2 件

FCS -> FDA Cumulative Estimated Daily Intake (CEDI)

FCS -> FDA Inventory of Food Contact Substances Listed in 21 CFR

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 6 件

This chemical does not meet GHS hazard criteria for 1.6% (35 of 2257) of reports.

Danger

H290 (34.6%): May be corrosive to metals [Warning Corrosive to Metals]

P234, P260, P264, P264+P265, P270, P273, P280, P301+P317, P301+P330+P331, P302+P361+P354, P304+P340, P305+P354+P338, P316, P317, P321, P330, P363, P390, P405, P406, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 2257 reports by companies from 33 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Danger

危険有害性情報

Regulatory Information · 4 件

Chemical: Phosphonic acid, (1-hydroxyethylidene)bis-

Phosphonic acid, P,P'-(1-hydroxyethylidene)bis- is listed on the EPA's Chemical Data Reporting (CDR) system. Manufacturers and importers of Phosphonic acid, P,P'-(1-hydroxyethylidene)bis- are required to report information about their production and use of this chemical to the EPA under the Toxic Substances Control Act (TSCA). (40 eCFR Part 711)

REACH registered substance: Etidronic acid (EC: 220-552-8)

Etidronic acid: Does not have an individual approval but may be used under an appropriate group standard

Other Safety InformationIMAP assessments - Etidronic acids: Human health tier II assessment
Hazards Summary · 1 件

No human data, but not expected to increase risk of congenital abnormalities based on animal studies; [REPROTOX] Safe to use as a sequestrant in food preparation; [JECFA] Causes gastrointestinal bleeding in lethal-dose feeding studies of mice; [RTECS] A corrosive substance that can cause injury to the skin, eyes, and respiratory tract; Inhalation may cause chemical pneumonitis; [MSDSonline]

Special Reports · 1 件

THE SYSTEMIC TOXICITY, SKIN TOLERANCE & ECOTOXICITY OF PRIMARY MATERIALS USED IN THE TREATMENT OF WATER, EG, ANTICORROSION PHOSPHONATES WAS STUDIED. HYDROXYETHANE DIPHOSPHONIC ACID HAD LOW TOXICITY & PRESENTED NO POTENTIAL HAZARD.[KASTNER W ET AL; TOXICITY AND ECOTOXICITY OF WATER TREATMENT PRODUCTS; L' EAU, L' INDUSTRIE, LES NUISANCES 72: 47 (1983)]

化学と産業

薬理情報

ATC Code · 2 件

M - Musculo-skeletal system

QM - Musculo-skeletal system

Pharmacodynamics · 1 件

Etidronic acid is a first generation bisphosphonate that inhibits the action of osteoclasts, preventing bone resporption. It has a wide therapeutic index as overdoses are not associated with severe toxicity and a long duration of action as it slowly releases from the bone. Patients should be counselled regarding the risk of upper gastrointestinal adverse reactions.

Mechanism of Action · 2 件

Bisphosphonates are taken into the bone where they bind to hydroxyapatite. Bone resorption by osteoclasts causes local acidification, releasing the bisphosphonate, which is taken into the osteoclast by fluid-phase endocytosis. Endocytic vesicles become acidified, releasing bisphosphonates into the cytosol of osteoclasts where they act. Osteoclasts mediate resorption of bone. When osteoclasts bind to bone they form podosomes, ring structures of F-actin. Disruption of the podosomes causes osteoclasts to detach from bones, preventing bone resorption. First generation bisphosphonates closely mimic the structure of pyrophosphate, which can be incorporated into ATP anologues that cannot be hydrolyzed, disrupting all ATP mediated actions of osteoclasts.

MALE RATS WERE INJECTED WITH VEHICLE (CONTROL GROUP), 0.4 OR 4.0 MG/KG/DAY OF ETHANE-1-HYDROXY-1,1-DIPHOSPHONATE (EHDP). AFTER 6 DAYS OF EHDP TREATMENT ALL RATS RECEIVED 6 SC INJECTIONS OF (3)H-THYMIDINE AT 8 HR INTERVALS. AFTER 6 DAYS OF EHDP PRE-TREATMENT THE MULTIPLE LABELING INDEX OF OSTEOPROGENITOR CELLS WAS REDUCED WITH 4.0 MG/KG/DAY DOSE OF EHDP. EHDP CAUSED INCR IN RATE OF INCORP & ACCUM OF (3)H-THYMIDINE NUCLEI IN OSTEOCLASTS. EHDP CAUSES AN ACCELERATED RATE OF OSTEOCLAST PRODN FROM PRECURSOR CELLS IN SPITE OF ITS ABILITY TO SLOW BONE RESORPTION.

Biological Half-LifeThe half life of etidronate is approximately 1-6 hours.
Metabolism/Metabolites · 2 件

Etidronic acid is not metabolized _in vivo_

Not metabolized. Route of Elimination: Etidronate disodium is not metabolized. Within 24 hours, approximately half the absorbed dose is excreted in urine; the remainder is distributed to bone compartments from which it is slowly eliminated. Unabsorbed drug is excreted intact in the feces. Half Life: In normal subjects, plasma half-life of etidronic acid, based on non-compartmental pharmacokinetics is 1 to 6 hours.

関連反応

11 件
反応記録を作成
HRID 253730 の反応式
HRID 253730生成物として
HRID 615828 の反応式
HRID 615828反応物として
HRID 615829 の反応式
HRID 615829反応物として
HRID 851233 の反応式
HRID 851233反応物として
HRID 1089373 の反応式
HRID 1089373反応物として
HRID 1089374 の反応式
HRID 1089374反応物として
HRID 1464227 の反応式
HRID 1464227反応物として
HRID 1751156 の反応式
HRID 1751156反応物として
前へ1 / 2 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
2809-21-4、7414-83-7
PubChem CID
3305
DTXSID
DTXSID6023028
ChEMBL
CHEMBL871
ChEBI
CHEBI:4907
UNII
M2F465ROXU
EC Number
220-552-8
Nikkaji
J7.915D
Physical Description · 3 件

CBI; Dry Powder; Liquid; Dry Powder; Liquid

White odorless powder; [MSDSonline]

Solid

物理化学的性質

融点
198 · 198~199℃
沸点
578.8 · 578.8±60.0 °C(Predicted)
比重(密度)
1.45 · 1.45 (60% aq.)
蒸気圧
0 Pa · 0Pa at 25℃
貯蔵温度
Sealed in dry,Room Temperature
溶解性
Methanol (Slightly), Water (Slightly)
酸解離定数(Pka)
1.35 · 1.35, 2.87, 7.03, 11.3(at 25℃)
外見
粉
色
白い
PH
pH (1.7→100, 25℃) : 1.3~1.8
水溶解度
水に溶ける。
Merck
14 · 14,3863
BRN
1789291 · 1789291
安定性
安定。強力な酸化剤とは相容れない。
化粧品成分の機能
キレート化
InChI
1S/C2H8O7P2/c1-2(3,10(4,5)6)11(7,8)9/h3H,1H3,(H2,4,5,6)(H2,7,8,9)
InChIKey
DBVJJBKOTRCVKF-UHFFFAOYSA-N
SMILES
CC(O)(P(O)(O)=O)P(O)(O)=O
LogP
-3.5 · -3.5
CAS データベース
2809 · 2809-21-4(CAS DataBase Reference)
EPAの化学物質情報
Etidronic acid (2809-21-4)

化学的性質

化学的特性light beige powder

EPA Safer ChemicalChemical: Etidronic acid
Hazard Classes and Categories · 3 件

Met. Corr. 1 (34.6%)

Acute toxicity - category 4

Acute toxicity (Oral) - Category 4

安全と保護具

Protective Action Criteria (PAC) · 3 件

4.3 [mg/m3]

48 [mg/m3]

290 [mg/m3]

毒性情報

Adverse EffectsDermatotoxin - Skin burns.
Exposure RoutesThe amount of drug absorbed after an oral dose is approximately 3%.
Toxicity Summary · 2 件

Safe in the present practices of use and concentration. Ingredient, concentration, and use information are available in documents discoverable at https://cir-reports.cir-safety.org

Bisphosphonates, when attached to bone tissue, are absorbed by osteoclasts, the bone cells that breaks down bone tissue. Although the mechanism of action of non-nitrogenous bisphosphonates has not been fully elucidated, available data suggest that they bind strongly to hydroxyapatite crystals in the bone matrix, preferentially at the sites of increased bone turnover and inhibit the formation and dissolution of the crystals. Other actions may include direct inhibition of mature osteoclast function, promotion of osteoclast apoptosis, and interference with osteoblast-mediated osteoclast activation. Etidronic acid does not interfere with bone mineralization. In malignancy-related hypercalcemia, etidronic acid decreases serum calcium by inhibiting tumour-induced bone resorption and reducing calcium flow from the resorbing bone into the blood. Etidronic acid also reduces morbidity of osteolytic bone metastases by inhibiting tumour-induced bone resorption. Etidronic acid may promote osteoclast apoptosis by competing with adenosine triphosphate (ATP) in the cellular energy metabolism. The osteoclast initiates apoptosis and dies, leading to an overall decrease in the breakdown of bone.

Signs and Symptoms · 1 件

Clinical experience with acute etidronic acid overdosage is extremely limited. Decreases in serum calcium following substantial overdosage may be expected in some patients. Signs and symptoms of hypocalcemia also may occur in some of these patients. Some patients may develop vomiting. In one event, an 18-year-old female who ingested an estimated single dose of 4800 to 6000 mg (67 to 100 mg/kg) of etidronate was reported to be mildly hypocalcemic (7 .5 2 mg/ dl) and experienced paresthesia of the fingers.

TSCA Test Submissions · 2 件

In a perinatal and postnatal study, pregnant female Long-Evans rats (20/group, except 21/high-dose group) were orally exposed by gavage to (1-hydroxyethylidene)bis-phosphonic acid at dose levels of 16.51, 110.09, or 330.28 mg/kg/day (in one-half doses, twice daily in deionized water; 10 ml/kg/day) on gestation day (GD) 15 through the end of gestation and the period of lactation. Surviving animals were sacrificed on lactation day 21. Significant differences were observed between treated and control animals in the following: decreased implantations/dam (high-dose group), decreased live fetuses/total fetuses (low-dose group), increased pup survival (lactation days 0-4, high-dose group), increased pup body weight (high- and mid-dose groups), and decreased number of females (mid-dose group). No significant differences were observed between treated and control animals in the following: pregnancy rate, length of gestation period, number of litters delivered, maternal weight gain, mortality, physical observations, or necropsy observations, numbers of pups/dam, live or dead fetuses/litter, live fetuses/implantation, pup sex ratios, and gross pup necropsy observations.

Teratogenicity was evaluated in pregnant Long-Evans rats (20/group) orally exposed by gavage to (1-hydroxyethylidene) bis-phosphonic acid at dose levels of 0, 16.51, 110.09 or 330.28 mg/kg/day (in deionized water solutions, 10 ml/kg/day, one-half doses given twice daily) on gestation days (GD) 6-15. All surviving rats were sacrificed on GD 20. Significant differences were observed between treated and control animals with respect to a decreased incidence of soft tissue abnormalities (low-dose group). No significant differences were observed between treated and control animals in the following: maternal mortality, body weight, body weight change, pregnancy rate, physical observations, numbers of corpora lutea, implantations, live fetuses, resorptions, implantation frequency, necropsy observations, percent viable or resorbed fetuses, fetal weight, crown-rump length, sex ratio, ossification variations, and skeletal malformations.

Human Toxicity ExcerptsIV ADMIN OF 5 MG 1-HYDROXYETHYLIDENE DIPHOSPHONATE (HEDP) DAILY TO YOUNG MALES FOR 5 DAYS DID NOT ALTER THE BLOOD & URINARY LEVELS OF CALCIUM & PHOSPHATE, & OTHER BIOCHEMICAL PARAMETERS.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 件

Benchmark Dataset for the Liver Toxicity Knowledge Base (LTKB)

etidronic acid

Didronel®

Bisphosphonates

Not Applicable

no-DILI-concern

Non-Human Toxicity Excerpts · 5 件

ETHANEHYDROXY DIPHOSPHONATE (EHDP) WAS ADMIN SC TO ADULT BEAGLE DOGS FOR 1-2 YR AT VARIOUS DOSE LEVELS TO DETERMINE ITS SKELETAL EFFECTS WHEN GIVEN CHRONICALLY. AT LOW DOSES (0.1 & 0.5 MG/KG/DAY), EHDP CAUSED A TIME-&-DOSE DEPENDENT REDN IN PERCENTAGE OF BONE SURFACE WITH ACTIVE MINERALIZATION, A REDN IN MINERALIZATION RATES, REDN IN RESORPTION SPACE, BUT NO CHANGES IN OSTEOID SEAM WIDTHS. EHDP CAN HAVE PROFOUND EFFECTS ON BONE REMODELING IN THE DOG, BUT THESE EFFECTS ARE DOSE-&-TIME-DEPENDENT & APPEAR TO BE REVERSIBLE.

THE ENERGY CHARGE OF THE ADENYLATE POOL & ATP & INORG PHOSPHATE CONTENT WERE NOT CHANGED BY TREATMENT OF CULTURED CALVARIA CELLS WITH ETHANE-1-HYDROXY-1,1-DIPHOSPHONATE.

FETAL MOUSE CALVARIA WERE CULTURED FOR 48 HR IN PRESENCE OF ETHANE-1-HYDROXY-1,1-DIPHOSPHONATE (EHDP) AFTER WHICH ACTIVITY OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE, 6-PHOSPHOGLUCONATE DEHYDROGENASE, HEXOKINASE, LACTATE DEHYDROGENASE, ACONITASE, & ISOCITRATE DEHYDROGENASE WAS DETERMINED. EHDP HAD NO EFFECT ON ANY OF THE ENZYMES STUDIED.

ETHANE-1-HYDROXY-1,1-DIPHOSPHONATE ADMIN TO IMMATURE RATS INHIBITED MINERALIZATION AS EVIDENCED BY WIDENED TIBIAL EPIPHYSEAL PLATES AND DECREASED BONE ASH TO DRY WT RATIOS.

For more Non-Human Toxicity Excerpts (Complete) data for 1-HYDROXY-1,1-DIPHOSPHONOETHANE (7 total), please visit the HSDB record page.

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

F
10
wgk
2
tsca
TSCA listed
rtecs
SZ8562100
ridadr
UN 3265
毒性
LD50 oral in mouse: 1800mg/kg
hs_code
2931900090
risk_code
37/38-41-22
化審法
(2)-2936 優先評価化学物質
hazard_code
Xi,Xn
safety_code
26-39
hazard_class
8
packing_group
II
Hazard Classifications
Eye Dam. 1Met. Corr. 1
ストレージクラス
8A - Combustible corrosive hazardous materials
有毒物質データの
2809-21-4(Hazardous Substances Data)
FDA Pharmacological Classification · 5 件

M2F465ROXU

ETIDRONIC ACID

Established Pharmacologic Class [EPC] - Bisphosphonate

Chemical Structure [CS] - Diphosphonates

Etidronic acid is a Bisphosphonate.

MeSH Pharmacological ClassificationAgents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.
Absorption, Distribution and Excretion · 6 件

Etidronic acid has an oral bioavailability of 1-10%. Further data regarding pharmacokinetics of etidronic acid are not readily available.

Absorbed etidronic acid is eliminated in the urine, while the unabsorbed drug is eliminated in the feces.

Etidronic acid has a volume of distribution of 0.3-1.3L/kg.

Etidronic acid has a renal clearance of 0.09L/kg/h.

THE DISTRIBUTION OF TECHNETIUM-99M HEDP IN NORMAL HUMAN ORGANS WAS MEASURED.

THE BONE-SEEKING AGENT (99M)TC-SN-1-HYDROXYETHYLIDENE-1,1-DIPHOSPHONIC ACID UNEXPECTEDLY BINDS TO PARTICLES OF HUMAN ARTICULAR CARTILAGE AS WELL AS CORTICAL BONE IN VITRO. MECHANISMS ADDITIONAL TO THE SIMPLE IONIC ATTRACTION BETWEEN THE PHOSPHONATE GROUPS OF HEDP & METAL CATIONS SUCH AS CA2+ ARE RESPONSIBLE FOR THE UPTAKE OF (99M)TC-HEDP BY BODY TISSUES.

Cellular LocationsMembrane

用途と製造

Uses · 6 件

CIR ingredient: Etidronic Acid

Used as a sequestering and chelating agent; as a scale and corrosion inhibitor; as a bone resorptions inhibitor; [Merck Index]

MEDICATION

MEDICATION (VET)

Use (kg; approx.) in Germany (2009): >1000

For the treatment of symptomatic Paget's disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury.

U.S. Exports · 2 件

(1979) No Data

(1981) No Data

U.S. Imports · 2 件

(1979) No Data

(1981) No Data

U.S. Production · 3 件

2023: 7,000,000 - <8,500,000 lb

(1979) PROBABLY GREATER THAN 2.27X10+6 GRAMS

(1981) PROBABLY GREATER THAN 2.27X10+6 GRAMS

Consumer UsesChelating agent
Industry UsesProcessing aids not otherwise specified
Methods of Manufacturing · 1 件

PASSAGE OF GASEOUS PHOSPHORUS TRICHLORIDE INTO ACETIC ACID; REACTION OF GASEOUS PHOSPHORUS TRICHLORIDE & ACETIC ACID IN A LOWER ALIPHATIC TERTIARY AMINE, EG, TRIBUTYLAMINE; REACTION OF AN ANHYDROUS MIXTURE OF PHOSPHOROUS ACID, ACETIC ANHYDRIDE, & ACETIC ACID

Household Products · 2 件

Information on 1 consumer products that contain Etidronic Acid in the following categories is provided:

Information on 253 consumer products that contain Etidronic acid in the following categories is provided:

Use Classification · 5 件

EPA Safer Chemical Functional Use Classes -> Oxidants and Oxidant Stabilizers

Safer Chemical Classes -> Yellow triangle - The chemical has met Safer Choice Criteria for its functional ingredient-class, but has some hazard profile issues

Fragrance Ingredients

Food Additives -> SEQUESTRANT -> JECFA Functional Classes

Cosmetics -> Chelating

General Manufacturing Information · 6 件

Utilities

Phosphonic acid, P,P'-(1-hydroxyethylidene)bis-: ACTIVE

WAVE-SETTING HAIR PREPARATIONS ARE PREPARED BY COMBINING L-CYSTEINE WITH 1-HYDROXYETHANE-1,1-DIPHOSPHONIC ACID. THE CHELATING AGENT PREVENTS FORMATION OF DANDRUFF.

CORROSION SCALE PREVENTION IN COOLING WATER TREATMENT BY ORGANOPHOSPHATES.

1-HYDROXYETHANE-1,1-DIPHOSPHONIC ACID IS USED IN HAIRSETTING PREPARATIONS. THE CHELATING AGENT PREVENTS FORMATION OF DANDRUFF.

1-HYDROXYETHYLDIPHOSPHONATE INCREASED BOVINE TOOTH ENAMEL ION-SELECTIVITY; THE EFFECT WAS RELATED TO THE NUMBER OF PHOSPHATE GROUPS & WAS GREATER WITH THE ORGANIC THAN INORGANIC PHOSPHATES.

応用分野 · 3 件

用途水処理剤,繊維処理剤,写真薬安定剤,金属表面処理剤,化粧品安定剤

用途水処理剤、金属表面処理剤、キレート剤。

使用Etidronate (Didronel) is a human protein tyrosine phosphatase inhibitor with IC50 of 0.2 μM.

上流・下流製品情報

上流原料

ジエチレントリアミンPhosphorus oxychloride三塩化りん塩酸酢酸N-Acetyl-D-galactosamine(galactose-13C6, 99%)

下流製品

(1-ヒドロキシエタン-1,1-ジイル)ビス(ホスホン酸ジナトリウム)NS series corrision and scale inhibitorsscale inhibitor and sipersant TS-104efficient complex formulationof corrosion and scale control
補足説明 · 2 件

定義本品は、次の化学式で表される有機ジホスホン酸である。

定義ChEBI: A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.